Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

Opinion|Videos|May 15, 2024

Staging and Treatment Decisions for Kidney Cancer

Author(s)Neal Shore, MD, FACS, Brian M. Shuch, MD

Brian Shuch, MD, and Neal Shore, MD, FACS, discuss the staging and treatment of kidney cancer, including when to biopsy and how often to do follow-up imaging.

Episodes in this series

Video 1 - "A Growing Incidence of Renal Masses"

EP. 1 A Growing Incidence of Renal Masses

Video 2 - "Diagnostic Tests for Kidney Cancer"

EP. 2 Diagnostic Tests for Kidney Cancer

EP. 3 Limitations of Conventional Imaging for Assessing Renal Masses

EP. 3 Limitations of Conventional Imaging for Assessing Renal Masses

Video 4 - "The Role of a Multidisciplinary Team in Managing Kidney Cancer"

EP. 4 The Role of a Multidisciplinary Team in Managing Kidney Cancer

Neal Shore, MD, FACS, and Brian M. Shuch, MD, experts on kidney cancer

EP. 5 Staging and Treatment Decisions for Kidney Cancer

Neal Shore, MD, FACS, and Brian M. Shuch, MD, experts on kidney cancer

EP. 6 Advances in Imaging for Kidney Cancer Diagnosis and Management

Neal Shore, MD, FACS, and Brian M. Shuch, MD, experts on kidney cancer

EP. 7 Overview of Clinical Trials for New Imaging Options for Kidney Cancer

Neal Shore, MD, FACS, and Brian M. Shuch, MD, experts on kidney cancer

EP. 8 Potential Impact of PET/CT Imaging on Improving Patient Care

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

FDA updates in urology: November 2025

ByHannah Clarke

December 1st 2025

FDA grants fast track designation to diagnostic agent for clear cell renal cell carcinoma

ByHannah Clarke

November 17th 2025

Andrew Hahn, MD, on the safety profile for lenvatinib/everolimus vs cabozantinib

ByAndrew W. Hahn, MD

November 14th 2025

Marc Machaalani, MD, on soluble MAdCAM-1 in metastatic renal cell carcinoma

ByMarc Machaalani, MD

November 11th 2025

Blurred interior of hospital | Image Credit: © jakkapan - stock.adobe.com

Urologist Elizabeth Mobley, MD, discusses advances in bladder and kidney cancer

ByElizabeth Mobley, MD

November 10th 2025

Latest CME

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Wisconsin

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Wisconsin

Scott T. Tagawa, MD, MS, FACP, FASCO; Kate Baxstrom, MD

DSUI Urology on the Beach

In-Person Event

DSUI Urology on the Beach

January 16-18, 2026

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk

Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk

Jason M. Hafron, MD

Guiding Prostate Cancer Diagnosis with Biomarker Testing

Guiding Prostate Cancer Diagnosis with Biomarker Testing

Aaron D. Berger, MD

Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis

Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis

Stacy Loeb, MD, MSc, PhD (Hon)

Trending on Urology Times

Sildenafil cream for female sexual arousal disorder available to prescribe in select states

Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men

Experts urge FDA to revisit labeling for testosterone replacement therapy in men

FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC

FDA approves zoliflodacin for uncomplicated urogenital gonorrhea

© 2025 MJH Life Sciences^®

All rights reserved.